肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2013年
5期
361-364
,共4页
二甲双胍%Folfox6%2型糖尿病%结直肠癌
二甲雙胍%Folfox6%2型糖尿病%結直腸癌
이갑쌍고%Folfox6%2형당뇨병%결직장암
Metformin%Folfox6%Type 2 diabetes mellitus%Colorectal cancer
目的:观察二甲双胍联合Folfox6治疗结直肠癌合并2型糖尿病的临床效果和安全性。方法将2007年3月至2008年8月在我院肿瘤科住院治疗的50例2型糖尿病合并结直肠癌的患者随机分成两组,二甲双胍组接受二甲双胍联合Folfox6治疗,非二甲双胍组接受其他糖尿病药物联合Folfox6治疗。结果二甲双胍组治疗总有效率为60%,非二甲双胍组治疗总有效率为36%,差异有统计学意义(P<0.05);二甲双胍组腹泻与呕吐与非二甲双胍组相比,差异有统计学意义(P<0.05);二甲双胍组的5年生存率显著高于非二甲双胍组,差异有统计学意义(P<0.05)。结论二甲双胍联合Folfox6能显著提高2型糖尿病合并结直肠癌患者的临床疗效,值得在临床推广应用。
目的:觀察二甲雙胍聯閤Folfox6治療結直腸癌閤併2型糖尿病的臨床效果和安全性。方法將2007年3月至2008年8月在我院腫瘤科住院治療的50例2型糖尿病閤併結直腸癌的患者隨機分成兩組,二甲雙胍組接受二甲雙胍聯閤Folfox6治療,非二甲雙胍組接受其他糖尿病藥物聯閤Folfox6治療。結果二甲雙胍組治療總有效率為60%,非二甲雙胍組治療總有效率為36%,差異有統計學意義(P<0.05);二甲雙胍組腹瀉與嘔吐與非二甲雙胍組相比,差異有統計學意義(P<0.05);二甲雙胍組的5年生存率顯著高于非二甲雙胍組,差異有統計學意義(P<0.05)。結論二甲雙胍聯閤Folfox6能顯著提高2型糖尿病閤併結直腸癌患者的臨床療效,值得在臨床推廣應用。
목적:관찰이갑쌍고연합Folfox6치료결직장암합병2형당뇨병적림상효과화안전성。방법장2007년3월지2008년8월재아원종류과주원치료적50례2형당뇨병합병결직장암적환자수궤분성량조,이갑쌍고조접수이갑쌍고연합Folfox6치료,비이갑쌍고조접수기타당뇨병약물연합Folfox6치료。결과이갑쌍고조치료총유효솔위60%,비이갑쌍고조치료총유효솔위36%,차이유통계학의의(P<0.05);이갑쌍고조복사여구토여비이갑쌍고조상비,차이유통계학의의(P<0.05);이갑쌍고조적5년생존솔현저고우비이갑쌍고조,차이유통계학의의(P<0.05)。결론이갑쌍고연합Folfox6능현저제고2형당뇨병합병결직장암환자적림상료효,치득재림상추엄응용。
Objective To explore the clinical effects and safety of metformin integrated with folfox6 treating colorectal cancer complicated with type 2 diabetes mellitus. Methods 50 cases with type 2 diabetes mellitus complicated with colorectal cancer ac-cepting treatment from March, 2007 to August, 2008 were divided randomly into two groups, the metformin group was treated with metformin as well as folfox6 while the non-metformin group was treated with other diabetes drug combined with folfox6. Results The total effective rate in the metformin group is 60%, it is statistical to compare that (36%) in the non-metformin group (P<0.05);there is also statistical meaning to compare the nausea and vomiting between the two groups (P<0.05);after 5 years of follow-up observation, the survival curve of the total cancer patients in the metformin group is higher than that of the non-metformin group, which is statistical (P<0.05). Conclusion Metformin integrated with folfox6 can improve the therapeutic effect on colorectal cancer complicated with type 2 diabetes mellitus, which worth promoting.